A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders

Trial Profile

A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Fonadelpar (Primary)
  • Indications Corneal disorders; Corneal injuries; Keratitis
  • Focus Therapeutic Use
  • Sponsors Senju Pharmaceutical
  • Most Recent Events

    • 07 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 17 Jun 2015 Planned End Date changed from 1 Feb 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov
    • 17 Jun 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Dec 2015,as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top